A pilot study of cerebral metabolism and serotonin 5-HT2A receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine.
Saved in:
| Title: | A pilot study of cerebral metabolism and serotonin 5-HT |
|---|---|
| Authors: | Egger K; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.; Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland., Gudmundsen F; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark., Jessen NS; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark., Baun C; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark., Poetzsch SN; Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland., Shalgunov V; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Copenhagen, Denmark., Herth MM; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Copenhagen, Denmark., Quednow BB; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland., Martin-Soelch C; Department of Psychology, University Fribourg, Fribourg, Switzerland., Dornbierer D; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland., Scheidegger M; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland., Cumming P; Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland.; School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia., Palner M; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.; Neurobiology Research Unit, Copenhagen University Hospital, Copenhagen, Denmark. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2023 Sep 28; Vol. 14, pp. 1140656. Date of Electronic Publication: 2023 Sep 28 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
